Compare Heron Therapeutics Inc (HRTX) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Orion Office REIT Inc — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Orion Office REIT Inc trades at $2.19 (market cap $125.50M). The key difference: Orion Office REIT Inc is the larger of the two by market cap, and Orion Office REIT Inc pays a 3.64% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Orion Office REIT Inc for 33 Days on average.
| HRTX | ONL | |
|---|---|---|
Market Cap | $68.01M | $125.50M |
Volume | 1,891,941 | 303,276 |
Sector | Health | Real Estate |
52-Week High | $1.49 | $3.00 |
52-Week Low | $0.27 | $1.93 |
Typical Hold Time | 35 Days | 33 Days |
Enterprise Value | $174.75M | $542.43M |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
ONL trades at $2.27, down 2.58% today, with a bearish technical signal from moving averages but bullish oscillators. The company shows declining revenue from $208M in 2022 to $148M in 2025, with persistent net losses widening to -$139M. Analyst consensus is split 50/50 buy/hold, while recent news highlights strategic portfolio repositioning and Q2 2026 earnings beat.
Outlook remains challenged by negative profitability and high debt levels, though low P/B of 0.2 suggests deep value. Key risks include office sector headwinds and cash flow volatility. Investment appeal hinges on successful execution of turnaround strategy amid weak fundamental trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
